secondary or tertiary alkylamine moiety and a neurokinin-1 (NK-1) receptor antagonist containing a primary, secondary or tertiary alkylamine moiety; and a CYP2D6 inhibitor in the manufacture of a medicament for the treatment of a human in need thereof wherein the drug and the inhibitor are no...
At least one CYP2D6 inhibitor, n (%) 38 (21.3%) 22 (17.2%) 16 (32.0%) 0.030 0.921 0.215–3.940 0.911 At least one CYP2C19 inhibitor, n (%) 8 (4.5%) 4 (3.1%) 4 (8.0%) 0.223 Antidepressants (presence), n (%) 52 (29.2%) 30 (23.4%) 22 (44.0%) 0.007 2.813 0.833–9.505...
Santa Cruz Biotechnology ofrece ahora una amplia gama de sustratos de CYP2D6 para su uso en diversas aplicaciones. CYP2D6 es una enzima clave de la familia del citocromo P450, responsable del metabolismo de una amplia variedad de compuestos endógenos y exógenos, incluidos neurotransmisores,...
Abstract The compound [K([2.2.2]crypt)]Cs7[Sn9]2(en)3 (1) was synthesized from an alloy of formal composition K... Baumann,Pierre 被引量: 0发表: 2014年 CLINICAL AND TOXICOLOGICAL RELEVANCE OF CYP2C9: Drug-Drug Interactions and Pharmacogenetics Annual Review of Pharmacology & ToxicologyRett...
Pedersen RS, Damkier P, Brosen K 2005 Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 77:458 – 467 7. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F 2007 Concen- trations of tramadol and O-desmethyltramadol ...
CYP2D6 UM showed the highest rate of polypharmacy, whilst, IM participants had the highest rates of neurological and psychiatric AEs, even worse if a CYP2D6 inhibitor drug was prescribed simultaneously. CYP2D6 pharmacogenomics and the monitoring of new antipsychotic prescriptions may make a difference...
Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can. J. Psychiatry 2020, 65, 521–530. [Google Scholar] [CrossRef] [PubMed] Gaedigk, A.; Ingelman-Sundberg, M.; Miller, N.A.; Leeder, J.S.; ...
52. Cartwright AL, Wilby KJ, Corrigan S, Ensom MH. Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother. 2013;47(3):350–360. 53. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences...
This is also interesting because LSD may be therapeutically used in patients with psychiatric disorders and using a serotonin reuptake inhibitor (SSRI) treatment, which may also act as CYP2D6 inhibitors (e.g., fluoxetine and paroxetine)41. Consideration should also be given to discontinuing CYP2D6...
J Halling,P Weihe,K Brosen - 《Therapeutic Drug Monitoring》 被引量: 130发表: 2008年 Multiple mutations of the human cytochrome P450 IID6 gene (CYP 2D6) in poor metabolizers of debrisoquine Further, the study aimed to investigate whether the previously observed frequency of CYP2D6 poor meta...